STAT

Experts challenge the science behind ban on psychiatrists discussing politicians’ mental health

A prohibition against psychiatrists discussing the mental health of public figures is “premised on dubious scientific assumptions,” researchers concluded.
Photos of Sen. Barry Goldwater during his 1964 campaign for president.

A prohibition against psychiatrists discussing the mental health of public figures — a rule that has become especially controversial, and sometimes flouted, since the inauguration of President Trump — is “premised on dubious scientific assumptions,” researchers concluded in an analysis scheduled for publication in a psychology journal.

The American Psychiatric Association (APA) defends its “” by arguing that an in-person psychiatric examination is the gold standard for diagnosing mental illness and psychological traits — given that there are no blood tests or brain scans for psychiatric disorders. In fact, however, numerous studies suggest that the interview-based exam can be misleading, psychologist Scott Lilienfeld of Emory University and colleagues argue in the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About The Purdue Bankruptcy Ruling, A Merck Rejection, And More
In today's Pharmalittle roundup, we're reading about the Purdue bankruptcy ruling, a Merck rejection, and more.
STAT1 min read
STAT+: How Controversial Was The Decision By FDA’s Peter Marks To Approve Sarepta’s Gene Therapy? Check Its Footnotes
The unilateral decision by Peter Marks, a top FDA official, to approve a gene therapy for Duchenne muscular dystrophy looks even more surprising on a close examination.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Alzheimer’s Drug, An EU Contract For Bird Flu Vaccine, And More
Advisers to the FDA voted unanimously to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly.

Related Books & Audiobooks